[EN] BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION<br/>[FR] DÉRIVÉS BIS-(SULFONYLAMINO) DESTINÉS AU TRAITEMENT DE LA DOULEUR ET DE L'INFLAMMATION
申请人:ASTRAZENECA AB
公开号:WO2010132016A1
公开(公告)日:2010-11-18
The invention provides compounds of formula (I) wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
The invention provides compounds of formula
wherein R
1
, R
2
, R
3
, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
[EN] BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066<br/>[FR] DÉRIVÉS BIS-(SULFONYLAMINO) DANS UNE THÉRAPIE 066
申请人:ASTRAZENECA AB
公开号:WO2009064251A1
公开(公告)日:2009-05-22
The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
The invention provides compounds of formula
wherein R
1
, R
3
, L
1
, L
2
, G
1
, G
2
, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
The invention provides compounds of formula
wherein R
1
, R
2
, R
3
, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.